Online inquiry

IVTScrip™ mRNA-Anti-ERBB2&ERBB3, MCLA-128(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11037MR)

This product GTTS-WQ11037MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets ERBB2&ERBB3 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001005862.3; NM_001005915.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2064; 2065
UniProt ID P04626; P21860
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB2&ERBB3, MCLA-128(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ11037MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11331MR IVTScrip™ mRNA-Anti-F, MEDI-524(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MEDI-524
GTTS-WQ6798MR IVTScrip™ mRNA-Anti-ERBB2, DS-8201(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA DS-8201
GTTS-WQ811MR IVTScrip™ mRNA-Anti-LRRC15, ABBV-085(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ABBV-085
GTTS-WQ5506MR IVTScrip™ mRNA-Anti-IL6, CDP 6038(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CDP 6038
GTTS-WQ1053MR IVTScrip™ mRNA-Anti-TNFRSF10B, ABBV-621(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ABBV-621
GTTS-WQ1924MR IVTScrip™ mRNA-Anti-VEGFA, AGN 150998(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA AGN 150998
GTTS-WQ9982MR IVTScrip™ mRNA-Anti-env, KD-247(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA KD-247
GTTS-WQ453MR IVTScrip™ mRNA-Anti-PDGFRA, 3G3(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA 3G3
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW